The Great Stem Cell Divide
By Michelle L. Brandt,
Stanford Medicine Magazine
| 09. 30. 2004
The science and politics of stem cell research
Stanford physician Michael Lyons, MD, is not a stem cell researcher. But when the Connecticut House Speaker recently called him to discuss her "cautious, maybe even negative, feelings" about a state bill that would endorse embryonic stem cell research, the Stanford genetics fellow was happy to oblige. The state lawmaker felt uneasy about portions of the bill, so Lyons patiently defined complex scientific terms, clarified the differences between this type of research and reproductive cloning, and outlined what he saw as the merits of the work.
By the end of the conversation he had convinced his mom that she should support the legislation.
Lyons and his mother, Speaker Moira Lyons, are just two of many to dive into the debate surrounding stem cells, undeveloped cells that can be coaxed into growing into any kind of tissue. Stem cells are so small that they can't be seen with the naked eye, yet they tend to cause mass confusion and evoke the largest of responses. In fact, Moira Lyons blames the bill's eventual failure to pass in the Connecticut House on legislators'...
Related Articles
By Carly Mallenbaum, Axios [cites Emily Galpern] | 03.29.2026
More Americans are turning to surrogacy to build their families, as the practice becomes more common and more publicly discussed.
Why it matters: As surrogacy becomes more visible and accessible, ethical, legal and cultural tensions become harder to ignore...
By Carly Mallenbaum, Axios [cites Surrogacy360] | 03.29.2026
Without a federal law, surrogacy in the U.S. is governed by a patchwork of state regulations/
Why it matters: Confusing, varied local rules can determine everything from whether agreements are legally binding to who is recognized as a parent at...
Cathy Tie seems to be good at starting businesses but not so dedicated to maintaining them. CGS, like many others, first heard of her thanks to Caiwei Chen and Antonio Regalado in MIT Technology Review, May 2025, as the partner (perhaps bride) of the notorious Chinese scientist He Jiankui, described in the headline as “China’s Frankenstein.” He prefers “Chinese Darwin.” She ran his Twitter account for a while, contributing such gems as:
Get in luddite, we’re going gene editing...
By Laura DeFrancesco, Nature Biotechnology | 03.17.2026
The first gene editors designed to fix genetic lesions in mutation-agnostic ways are poised to enter the clinic. Tessera Therapeutics and Alltrna, two Flagship Pioneering-funded companies, are gearing up to test novel genetic medicines in humans. Tessera received regulatory clearance...